%0 Journal Article
%T Evaluation of Hospitalized Patients Receiving High versus Low-Dose Opioids for Non-Cancer Pain.
%A Moore CH
%A March KL
%A Hudson JQ
%A Finch CK
%A Twilla JD
%A Moore CH
%A March KL
%A Hudson JQ
%A Finch CK
%A Twilla JD
%A Moore CH
%A March KL
%A Hudson JQ
%A Finch CK
%A Twilla JD
%J J Pain Palliat Care Pharmacother
%V 36
%N 2
%D Jun 2022
%M 35648759
暂无%R 10.1080/15360288.2022.2063470
%X Limited studies suggest that opioid-related adverse effects (ORAEs) may worsen hospitalized patient outcomes, but there is insufficient data related to the impact of high-dose opioids compared to low-dose on adverse patient events. Given the paucity of data, our study aims to evaluate these ORAEs in the general hospitalized patient with non-cancer pain. A retrospective study of adult patients receiving opioids with a primary diagnoses of myocardial infarction, chronic obstructive pulmonary disease, heart failure, pneumonia, sepsis, or diabetes was conducted. Average oral morphine milligram equivalents (MMEs) administered over the entire LOS was collected, and patients were categorized as high-dose (≥50 MMEs/day) or low-dose (<50 MMEs/day). The primary composite endpoint was the incidence of ORAEs (naloxone use, decreased oxygen saturations, nausea/vomiting). Secondary outcomes included LOS, 30-day readmission, ORAEs with >100 MMEs/day. A total of 100 patients were included (n = 58 low-dose group; n = 42 high-dose group). For the primary outcome, more patients in the high-dose group experienced ORAEs (50% high-dose vs. 22.4% low-dose; p < 0.006). No statistically significant differences in LOS or 30-day readmission rates were identified between the groups. For patients receiving >100 MMEs/day, ORAEs occurred in 61% of patients. Hospitalized patients receiving high-dose opioids for non-cancer pain may have an increased incidence of ORAEs.